Folic acid supplementation for pregnant women and those planning pregnancy: 2015 update

During the last decade critical new information has been published pertaining to folic acid supplementation in the prevention of neural tube defects (NTDs) and other folic acid–sensitive congenital malformations. These new data have important implications for women, their families, and health care professionals. We performed a review looking for the optimal dosage of folic acid that should be given to women of reproductive age who are planning or not avoiding conception to propose updated guidelines and thus help health care providers and patients. In addition to fortification of dietary staples with folic acid, women of reproductive age should supplement before conception with 0.4‐1.0 mg of folic acid daily as part of their multivitamins. In the United States all enriched rice is also fortified with folic acid at 0.7 mg per pound of raw rice. However, this is not the case in many countries, and it has been estimated that only 1% of industrially milled rice is fortified with folic acid. In countries where rice is the main staple (eg, China), this does not allow effective folate fortification. Whereas the incidence of NTDs is around 1/1000 in the United States, it is 3‐ to 5‐fold higher in Northern China and 3‐fold higher in India. A recent population‐based US study estimated that the reduction in NTD rates by folic acid is more modest than previously predicted. The potential of NTD prevention by folic acid is underutilized due to low adherence with folic acid supplementation, and calls for revising the policy of supplementation have been raised. We identified groups of women of reproductive age who may benefit from higher daily doses of folic acid, and this should be considered in current practice. These include women who have had previous pregnancies with NTDs, those who did not plan their pregnancy and hence did not supplement, and women with low intake or impaired adherence to daily folic acid supplementation. In addition, women with known genetic variations in the folate metabolic cycle, those exposed to medications with antifolate effects, smokers, diabetics, and the obese may benefit from higher doses of folic acid daily during the first trimester.

[1]  G. Koren,et al.  Dose-Dependent Risk of Malformations With Antiepileptic Drugs: An Analysis of Data From the EURAP Epilepsy and Pregnancy Registry , 2015, Therapeutic drug monitoring.

[2]  G. Koren,et al.  Association Between Use of Oral Contraceptives and Folate Status: A Systematic Review and Meta-Analysis. , 2015, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[3]  G. Koren,et al.  Pregnancy‐induced changes in the long‐term pharmacokinetics of 1.1 mg vs. 5 mg folic acid: A randomized clinical trial , 2015, Journal of clinical pharmacology.

[4]  R. Kirby,et al.  Updated Estimates of Neural Tube Defects Prevented by Mandatory Folic Acid Fortification — United States, 1995–2011 , 2015, MMWR. Morbidity and mortality weekly report.

[5]  Figo Working Group On Best Practice In Maternal-Fe Best practice in maternal–fetal medicine , 2015, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[6]  A. Tardón,et al.  Folic acid supplements during pregnancy and child psychomotor development after the first year of life. , 2014, JAMA pediatrics.

[7]  H. Boezen,et al.  Maternal high‐dose folic acid during pregnancy and asthma medication in the offspring , 2014, Pharmacoepidemiology and drug safety.

[8]  O. Devine,et al.  Population red blood cell folate concentrations for prevention of neural tube defects: bayesian model , 2014, BMJ : British Medical Journal.

[9]  Zhi-Ping Wang,et al.  Maternal passive smoking during pregnancy and neural tube defects in offspring: a meta-analysis , 2014, Archives of Gynecology and Obstetrics.

[10]  M. Werler,et al.  The impact of folic acid intake on the association among diabetes mellitus, obesity, and spina bifida. , 2013, American journal of obstetrics and gynecology.

[11]  Zhi-Ping Wang,et al.  Maternal overweight and obesity and the risk of neural tube defects: a case-control study in China. , 2013, Birth defects research. Part A, Clinical and molecular teratology.

[12]  K. Bradbury,et al.  Differences in erythrocyte folate concentrations in older adults reached steady-state within one year in a two-year, controlled, 1 mg/d folate supplementation trial. , 2012, The Journal of nutrition.

[13]  A. Ly,et al.  Folate and DNA methylation. , 2012, Antioxidants & redox signaling.

[14]  Burcu Kara,et al.  Simultaneous folate intake may prevent advers effect of valproic acid on neurulating nervous system , 2012, Child's Nervous System.

[15]  T. Tomson,et al.  Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry , 2011, The Lancet Neurology.

[16]  D. Maneval,et al.  MTHFR 677C->T genotype is associated with folate and homocysteine concentrations in a large, population-based, double-blind trial of folic acid supplementation. , 2011, The American journal of clinical nutrition.

[17]  G. Koren,et al.  Folate intake and the risk of colorectal cancer: a systematic review and meta-analysis. , 2011, Cancer epidemiology.

[18]  P. Hider,et al.  Folic acid supplementation and colorectal cancer risk: a meta‐analysis , 2011, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[19]  W. Willett,et al.  Pooled analyses of 13 prospective cohort studies on folate intake and colon cancer , 2010, Cancer Causes & Control.

[20]  G. Koren,et al.  Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations. , 2009, British journal of clinical pharmacology.

[21]  L. Bailey,et al.  Folate in Health and Disease , 2009 .

[22]  A. Ren,et al.  Association of reduced folate carrier gene polymorphism and maternal folic acid use with neural tube defects , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[23]  G. Koren,et al.  Predictors of Prenatal Multivitamin Adherence in Pregnant Women , 2009, Journal of clinical pharmacology.

[24]  G. Koren,et al.  Steady state folate concentrations achieved with 5 compared with 1.1 mg folic acid supplementation among women of childbearing age. , 2009, The American journal of clinical nutrition.

[25]  R. Rozen,et al.  Valproic acid increases expression of methylenetetrahydrofolate reductase (MTHFR) and induces lower teratogenicity in MTHFR deficiency , 2008, Journal of cellular biochemistry.

[26]  G. Koren,et al.  Folate fortification and supplementation--are we there yet? , 2008, Reproductive toxicology.

[27]  B. de Benoist Conclusions of a WHO Technical Consultation on Folate and Vitamin B12 Deficiencies , 2008, Food and nutrition bulletin.

[28]  E. Merello,et al.  Evaluation of a methylenetetrahydrofolate-dehydrogenase 1958G>A polymorphism for neural tube defect risk , 2006, Journal of Human Genetics.

[29]  G. Koren,et al.  Celiac disease during pregnancy. , 2004, Canadian family physician Medecin de famille canadien.

[30]  J. M. Sequeira,et al.  Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. , 2004, The New England journal of medicine.

[31]  S. Buyske,et al.  New 19 bp deletion polymorphism in intron‐1 of dihydrofolate reductase (DHFR): A risk factor for spina bifida acting in mothers during pregnancy? , 2004, American journal of medical genetics. Part A.

[32]  G. Shaw,et al.  Associations between polymorphisms within the thymidylate synthase gene and spina bifida. , 2003, Birth defects research. Part A, Clinical and molecular teratology.

[33]  R. Finnell,et al.  Reduced folate carrier polymorphism (80A→G) and neural tube defects , 2003, European Journal of Human Genetics.

[34]  R. Finnell,et al.  Study of MTHFR and MS polymorphisms as risk factors for NTD in the Italian population , 2002, Journal of Human Genetics.

[35]  G. Shaw,et al.  Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. , 2002, American journal of medical genetics.

[36]  M. Law,et al.  Quantifying the effect of folic acid , 2001, The Lancet.

[37]  Quanhe Yang,et al.  5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. , 2000, American journal of epidemiology.

[38]  M. Werler,et al.  Achieving a public health recommendation for preventing neural tube defects with folic acid. , 1999, American journal of public health.

[39]  D. Weir,et al.  Folate levels and neural tube defects. Implications for prevention. , 1995, JAMA.

[40]  A. Czeizel,et al.  Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. , 1992, The New England journal of medicine.

[41]  M. Gnant,et al.  Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study , 1991, The Lancet.

[42]  Zhiping Wang,et al.  High dose of maternal folic acid supplementation is associated to infant asthma. , 2015, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[43]  A. Carriquiry,et al.  Folic acid source, usual intake, and folate and vitamin B-12 status in US adults: National Health and Nutrition Examination Survey (NHANES) 2003-2006. , 2010, The American journal of clinical nutrition.

[44]  G. Koren,et al.  Comparing folic acid pharmacokinetics among women of childbearing age: single dose ingestion of 1.1 versus 5 MG folic acid. , 2008, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[45]  G. Steger,et al.  Folate absorption in Crohn's disease. , 1994, Digestion.